What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Despite cost cuts, Moderna posted a second straight quarterly loss. It now sees 2024 sales ranging between $3 billion and $3.5 billion, down from its previous outlook of about $4 billion ...

Moderna is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.The company said the new ...

Moderna fell over 7% in premarket trading on Monday amid a broader selloff in global stocks. The Cambridge, Massachusetts-based biotech slashed its outlook for annual product sales last week ...

Shares of Moderna Inc. were plunging in early trading Monday, after the biotechnology company provided a downbeat revenue outlook and said it expects to burn more than $3 billion in cash in 2025.

Moderna Inc.’s third-quarter revenue fell by nearly a third and the pharmaceutical company cut its outlook, saying as part of its earnings report that supply constraints for its Covid-19 ...

Moderna is sticking by its forecast range for 2023 Covid-19 vaccine sales, after rival [Pfizer cut the sales outlook for its own shot](https: ...

Moderna Inc. shares moved lower Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and lowered full-year sales guidance by up to $3 billion.